特应性皮炎（AD）是一种常见的慢性瘙痒性皮肤病，成人和儿童皆可累及。其中儿童AD较成人更为常见，且 病情顽固，往往迁延不愈。由于婴幼儿药物选择存在局限性，儿童AD的药物治疗仍面临巨大的挑战。除外用糖皮质激素、 钙调磷酸酶抑制剂等传统治疗外，近期针对AD发病机制相关的小分子靶向抑制剂及生物制剂逐渐被应用于临床，文章就 此进行综述。

　Atopic dermatitis (AD) is a chronic, pruritus skin disease, which can affect both adults and children. It is more common in children and is difficult to cure in a short time. Due to limitations of drug selection in infants and children, there are great challenges in the treatment of pediatric AD. In addition to traditional treatments such as topical corticosteroids and calcineurin inhibitors, small-molecule inhibitors and biological agents targeting specific inflammatory pathway in the pathogenesis of AD have been gradually in clinical use. This paper reviews therapies currently available to pediatric AD.